FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283172394> ?p ?o ?g. }

• W4283172394 abstract "<h3>Introduction</h3> The incidence of sporadic Hepatitis E virus (HEV) is on the rise. Immunocompromised patients are at increased risk of developing chronic HEV resulting in increased morbidity and mortality. Ribavirin is used in the treatment of chronic Hepatitis E but there is little data on the safety and efficacy of treating patients with acute HEV. <h3>Methods</h3> We extracted data from hospital medical records on all patients with HEV infection treated with ribavirin over a period of five years. Hepatitis E infection was defined as clinical Hepatitis with raised alanine transaminase (ALT) and positive IgM serology or polymerase chain reaction (PCR). Comparison was made with age and sex matched controls with acute HEV infection, not treated with ribavirin. The primary outcome was to study: a. Sustained virological response (SVR) defined by negative HEV PCR at 12 weeks of treatment. Secondary outcome measures include: a. Mean time taken for normalization of ALT values. b. Development of anaemia with the use of ribavirin, defined as decrease in haemoglobin by more than 3g/dL from baseline attributed to ribavirin use. <h3>Results</h3> 15 immunocompromised patients (67% on post renal transplant immunosuppression and 33% on chemotherapy) with acute HEV were treated with ribavirin. Mean age was 60 +/-13.7 years with 60% males. They were given 10-12 weeks of ribavirin dosed at 400-600 mg per day. Mean ALT, aspartate aminotransferase (AST), and bilirubin and standard error at start of treatment were 310 ± 19 U/l, 321 ± 27.3 U/l and 49.5 ± 4.39 umol/l respectively. SVR was seen in 87.5% of patients. Mean time taken for normalisation of ALT was 24 ± 13 days. 20% of patients had anaemia with none being symptomatic or requiring transfusion. No adverse events were seen related to ribavirin use. Specifically, no patients had decompensation of liver disease with ribavirin use. In the control group the mean ALT, AST and bilirubin at presentation were 1137 ± 367 U/L, 806 ± 226 U/L and 51 ± 28 umol/l respectively. Mean time taken for normalisation of ALT was 51 ± 28 days. There was one mortality in the non-treated group due to decompensated liver disease. <h3>Conclusions</h3> Ribavirin is effective in the treatment of acute HEV and reduces morbidity and time taken for normalisation of ALT. Ribavirin is tolerated well with few adverse effects." @default.
• W4283172394 created "2022-06-21" @default.
• W4283172394 creator A5040651361 @default.
• W4283172394 creator A5061323066 @default.
• W4283172394 date "2022-06-01" @default.
• W4283172394 modified "2023-10-18" @default.
• W4283172394 title "P81 Acute hepatitis E and ribavirin treatment. A teaching hospital experience in Singapore" @default.
• W4283172394 doi "https://doi.org/10.1136/gutjnl-2022-bsg.138" @default.
• W4283172394 hasPublicationYear "2022" @default.
• W4283172394 type Work @default.
• W4283172394 citedByCount "0" @default.
• W4283172394 crossrefType "proceedings-article" @default.
• W4283172394 hasAuthorship W4283172394A5040651361 @default.
• W4283172394 hasAuthorship W4283172394A5061323066 @default.
• W4283172394 hasConcept C126322002 @default.
• W4283172394 hasConcept C203014093 @default.
• W4283172394 hasConcept C2522874641 @default.
• W4283172394 hasConcept C2776029263 @default.
• W4283172394 hasConcept C2776408679 @default.
• W4283172394 hasConcept C2776455275 @default.
• W4283172394 hasConcept C2777159539 @default.
• W4283172394 hasConcept C2778606649 @default.
• W4283172394 hasConcept C2780040827 @default.
• W4283172394 hasConcept C2780252810 @default.
• W4283172394 hasConcept C71924100 @default.
• W4283172394 hasConcept C90924648 @default.
• W4283172394 hasConceptScore W4283172394C126322002 @default.
• W4283172394 hasConceptScore W4283172394C203014093 @default.
• W4283172394 hasConceptScore W4283172394C2522874641 @default.
• W4283172394 hasConceptScore W4283172394C2776029263 @default.
• W4283172394 hasConceptScore W4283172394C2776408679 @default.
• W4283172394 hasConceptScore W4283172394C2776455275 @default.
• W4283172394 hasConceptScore W4283172394C2777159539 @default.
• W4283172394 hasConceptScore W4283172394C2778606649 @default.
• W4283172394 hasConceptScore W4283172394C2780040827 @default.
• W4283172394 hasConceptScore W4283172394C2780252810 @default.
• W4283172394 hasConceptScore W4283172394C71924100 @default.
• W4283172394 hasConceptScore W4283172394C90924648 @default.
• W4283172394 hasLocation W42831723941 @default.
• W4283172394 hasOpenAccess W4283172394 @default.
• W4283172394 hasPrimaryLocation W42831723941 @default.
• W4283172394 hasRelatedWork W10320147 @default.
• W4283172394 hasRelatedWork W14869090 @default.
• W4283172394 hasRelatedWork W17747543 @default.
• W4283172394 hasRelatedWork W19205177 @default.
• W4283172394 hasRelatedWork W19385909 @default.
• W4283172394 hasRelatedWork W2545228 @default.
• W4283172394 hasRelatedWork W2979338 @default.
• W4283172394 hasRelatedWork W5061555 @default.
• W4283172394 hasRelatedWork W5904294 @default.
• W4283172394 hasRelatedWork W7974271 @default.
• W4283172394 isParatext "false" @default.
• W4283172394 isRetracted "false" @default.
• W4283172394 workType "article" @default.